跳至主要内容
临床试验/NL-OMON55871
NL-OMON55871已完成2 期

A prospective follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW - Detection of Early Esophageal Cancer by NIR-FME. ESCEND

niversitair Medisch Centrum Groningen0 个研究点目标入组 25 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Suspicion or diagnosed LGD, HGD or superficial EAC and planned diagnostic
  • and/or therapeutic - endoscopy.
  • - Age: 18 years or older.
  • - Written informed consent.

排除标准

  • - Patients younger than 18 years old
  • - Submucosal and invasive EAC; EAC with TNM-classification other than T1.
  • - Radiation therapy for esophageal cancer
  • - Immunoglobulin allergy
  • - Chemotherapy, immunotherapy or surgery 28 days before administration of the
  • - Prior Bevacizumab or Cetuximab treatment
  • - Patients using anti-epileptic drugs (only exclusion criterium for the ICG
  • - Non-adjustable hypertension
  • - Medical or psychiatric conditions that compromise the patient*s ability to
  • give informed consent.
  • - Pregnancy or breast feeding.

研究者

相似试验